Physician profile
Mathew Gerving
NPI 1285243543
$1,174.94
in general payments reported to CMS, 2019-2025
18 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $163 · 2024: $696 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $241.71 | 2023-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $226.73 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.05 | 2024-2025 | Caplyta |
| Lundbeck LLC | $115.18 | 2023-2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.38 | 2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $50.03 | 2023-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $43.97 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.07 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $40.44 | 2024-2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $35.26 | 2025 | Trintellix |
| Neurocrine Biosciences, INC. | $32.77 | 2025 | |
| Exact Sciences Corporation | $30.63 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $27.18 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $19.50 | 2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $17.83 | 2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $15.54 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $15.23 | 2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.44 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Gerving listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.